
    
      The study will consist of a 2 week treatment period with participants injecting their current
      therapy of Copaxone 20 mg/1.0 mL glatiramer acetate utilizing an autoject 2. All participants
      will then roll over to the new formulation of 20 mg/0.5 mL glatiramer acetate with an
      autoject 2 device for a 4 week treatment period. Patient satisfaction will be evaluated using
      an Experience Questionnaire throughout the study.
    
  